CHN2 Promoter Methylation Change May Be Associated With Methamphetamine Dependence.
paper
Cited
Public
- Authors
- Hao, Liu; Luo, Tao; Dong, Huixi; Tang, Aiguo; Hao, Wei
- Year
- 2017
- Journal
- Shanghai archives of psychiatry
- PMID
- 29719347
- DOI
- 10.11919/j.issn.1002-0829.217100
- PMCID
- PMC5925587
BACKGROUND: Methamphetamine (MA) abuse is becoming increasingly serious in China. The mechanism of MA dependence remains unclear. CHN2 gene encodes chimeric protein-2 that regulate axonal pruning via the Rac-GTPase system and play a pivotal role in the formation of nervous circuits. Genetic studies suggest that the polymorphism of the CHN2 gene was related to substance dependence. AIMS: The aim of this study was to investigate the association between the methylation of CHN2 gene promoter with MA dependence. METHODS: According to SCID-I (Structured Clinical Interview for DSM-IV Axis I Disorders, SCID-I) used for investigating MA dependence, 224 male MA addicts were recruited into the case group. In addition, 109 healthy men were recruited into the control group. Blood samples were collected with the purpose of detecting the methylation levels of CHN2 gene promoter by methylight qPCR. The association between the methylation of CHN2 gene promoter with MA dependence was analyzed. RESULTS: The mean (sd) methylation levels of CHN2 gene promoter in the case group were significantly higher than in the control group, which were 2795.55 (733.19) and 1026.73 (698.73), respectively, showing significant differences between the two groups (t=21.25, p<0.001). Pearson analysis showed no significant correlation between the methylation levels of CHN2 promoter and other factors (the age of initial MA use, the duration of MA use, combination with K powder, tobacco and alcohol). CONCLUSIONS: The abnormal methylation of CHN2 gene promoter was significantly correlated with MA dependence.
The flowchart of the study
Comparison of methylation levels of CHN2 gene between those with MA addiction and healthy controls
Comparison of non-methylation levels of CHN2 gene between those with MA addiction and healthy controls
Electrophoresis profiling of CHN2 gene promoter sequences
1β17 of 17
| Name | Type |
|---|---|
| 2xES Taq Master Mix local | drug |
| addiction | phenotype |
| Age of initial MA use local | phenotype |
| alcohol | phenotype |
| alertness | phenotype |
| amphetamine-type stimulants | drug |
| attention | phenotype |
| cardiac acceleration local | phenotype |
| case group | cohort |
| Chimeric protein-2 local | drug |
| Chinese | cohort |
| CHN2 local | gene |
| CHN2 methylation local | phenotype |
| CHN2 non-methylation local | phenotype |
| CHN2 polymorphism local | variant |
| CHN2 promoter methylation local | phenotype |
| common living environments local | cohort |
| compulsory detoxification centers local | cohort |
| control group | cohort |
| cytosine | drug |
| ddH2O | drug |
| diglyceride local | drug |
| DNA | drug |
| DNA methylation | drug |
| DNA standard local | drug |
| DNA template local | drug |
| dopamine | drug |
| downstream primer local | drug |
| Downstream primer local | drug |
| drug abusers local | phenotype |
| Duration of MA use local | phenotype |
| euphoria | phenotype |
| EZ DNA Methylation-GoldTM Kit local | drug |
| fatigue | phenotype |
| Goldstar TaqMan mixture local | drug |
| healthy | phenotype |
| healthy controls | cohort |
| Healthy men local | phenotype |
| hippocampus | anatomy |
| hypertension | phenotype |
| JNK | gene |
| K powder local | drug |
| lifestyle local | phenotype |
| MA addiction group local | cohort |
| MA addicts local | cohort |
| MA-induced psychotic disorder | phenotype |
| MA onset age local | phenotype |
| MA use duration local | phenotype |
| methamphetamine | drug |
| methamphetamine dependence | phenotype |
| Methamphetamine use local | drug |
| Methylated probe local | drug |
| Modified DNA template local | drug |
| nicotine dependence | phenotype |
| norepinephrine | drug |
| occupational environment local | phenotype |
| phorbol ester local | drug |
| psychoactive substances | drug |
| Rac local | gene |
| RAC1 | gene |
| Rac GTPase system local | drug |
| RNase-free water | drug |
| schizophrenia | phenotype |
| serotonin | drug |
| spectrophotometer local | drug |
| stress | phenotype |
| synthetic drug abusers local | phenotype |
| synthetic drugs local | drug |
| tobacco dependence | phenotype |
| tobacco use | phenotype |
| Unmethylated probe local | drug |
| upstream primer local | drug |
| Upstream primer local | drug |
| uracil | drug |
| vigor local | phenotype |
No uploaded files.
Not in any collection.
| Citation | PMID | DOI | Status |
|---|---|---|---|
| Barrio-RealLBarruecoMGonzΓ‘lez-SarmientoRCalocaMJ Association of a novel polymorphism of the Ξ²2-Chimaerin gene (CHN2) with smoking. J Invest Med. 2013; 61: 1129-1131. doi: http://dx.doi.org/10.2310/JIM.0b013e3182a32ff910.2310/JIM.0b013e3182a32ff923941981 | β | β | β |
| CalocaMJWangHKazanietzMG Characterization of the Rac-GAP (Rac-GTPaseYactivating protein) activity of beta2-chimaerin, a βnon-protein kinase Cβ phorbol ester receptor. Biochem J. 2003; 375: 313Y321. doi: http://dx.doi.org/10.1042/BJ200307271287765510.1042/BJ20030727PMC1223697 | β | β | β |
| CruickshankCCDyerKR A review of the clinical pharmacology of methamphetamine. Addiction. 2009; 104: 1085-1099. doi: http://dx.doi.org/10.1111/j.1360-0443.2009.02564.x1942628910.1111/j.1360-0443.2009.02564.x | β | β | β |
| HaoWZhaoMLiJ. [Addiction Medicine: Theory and Practice]. Beijing: Peopleβs Medical Publishing House; 2016. Chinese | β | β | β |
| HashimotoRYoshidaMKunugiHOzakiNYamanouchiYIwataN A missense polymorphism (H204R) of a Rho GTPase-activating protein, the chimerin 2 gene, is associated with schizophrenia in men. Schizophr Res. 2005; 73: 383Y385. doi: http://dx.doi.org/10.1016/j.schres.2004.01.0171565328810.1016/j.schres.2004.01.017 | β | β | β |
| KanazawaTIkedaMGlattSJKikuyamaHKawamuraYNishidaN Genome-wide association study of atypical psychosis. Am J Med Genet B Neuropsychiatr Genet. 2013; 162B(7): 679-686. doi: http://dx.doi.org/10.1002/ajmg.b.321642413290010.1002/ajmg.b.32164 | β | β | β |
| KenneyJWFlorianCPortugalGSAbelTGouldTJ Involvement of hippocampal jun-N terminal kinase pathway in the enhancement of learning and memory by nicotine. Neuropsychopharmacology. 2010; 35(2): 483-492. doi: http://dx.doi.org/10.1038/npp.2009.1531977673010.1038/npp.2009.153PMC2794924 | β | β | β |
| LeachPTKenneyJWGouldTJ c-Jun-N-terminal kinase 1 is necessary for nicotine-induced enhancement of contextual fear conditioning. Neurosci Lett. 2016; 627: 61-64. doi: http://dx.doi.org/10.1016/j.neulet.2016.05.0482723557910.1016/j.neulet.2016.05.048PMC4939116 | β | β | β |
| LindPAMacgregorSVinkJMPergadiaMLHansellNKde MoorMH A genomewide association study of nicotine and alcohol dependence in Australian and Dutch populations. Twin Res Hum Genet. 2010; 13: 10Y29. doi: http://dx.doi.org/10.1375/twin.13.1.102015830410.1375/twin.13.1.10PMC3070599 | β | β | β |
| LinSManTNLiHLSongRWangGC [Research progress on qualitative analysis methods of methamphetamine]. Zhongguo Yao Wu Lan Yong Fang Zhi Za Zhi. 2016; 22: 58-62. Chinese. doi: http://dx.chinadoi.cn/10.15900/j.cnki.zylf1995.2016.01.024 | β | β | β |
| LiuQRDrgonTJohnsonCWaltherDHessJUhlGR Addiction molecular genetics: 639,401 SNP whole genome association identifies many βcell adhesionβ genes. Am J Med Genet B Neuropsychiatr Genet. 2006; 141B(8): 918-925. doi: http://dx.doi.org/10.1002/ajmg.b.304361709988410.1002/ajmg.b.30436 | β | β | β |
| NotcovichCDiezFTubioMRBaldiAKazanietzMGDavioC Histamine acting on H1 receptor promotes inhibition of proliferation via PLC, RAC, and JNK-dependent pathways. Exp Cell Res. 2010; 316: 401-411. doi: http://dx.doi.org/10.1016/j.yexcr.2009.11.0021991301310.1016/j.yexcr.2009.11.002 | β | β | β |
| PanenkaWJProcyshynRMLecomteTMacEwanGWFlynnSWHonerWG Methamphetamine use: a comprehensive review of molecular, preclinical and clinical findings. Drug Alcohol Depend. 2013; 129: 167-179. http://dx.doi.org/10.1016/j.drugalcdep.2012.11.0162327377510.1016/j.drugalcdep.2012.11.016 | β | β | β |
| RiccomagnoMMHurtadoAWangHBMacopsonJGGrinerEMBetzA The RacGAP A2-Chimaerin selectively mediates axonal pruning in the hippocampus. Cell. 2012; 149: 1594Y1606. doi: http://dx.doi.org/10.1016/j.cell.2012.05.0182272644410.1016/j.cell.2012.05.018PMC3395473 | β | β | β |
| SchmidtHDMcGintyJFWestAESadri-VakiliG. Epigenetics and psychostimulant addiction. Cold Spring Harb Perspect Med. 2013; 3(3): a012047. doi: http://dx.doi.org/10.1101/cshperspect.a01204710.1101/cshperspect.a012047PMC357920323359110 | β | β | β |
| The office of National Narcotics Control Commission. Chinese drug control report in 2017 [Internet]. China drug control network [cited 2017 July]. Available from: http://www.nncc626.com/2017-03/30/c_129521742.htm | β | β | β |
| UhlGRLiuQRDrgonTWaltherDRoseJEDavidSP Molecular genetics of successful smoking cessation: convergent genome-wide association study results. Arch Gen Psychiatry. 2008; 65: 683Y693. doi: http://dx.doi.org/10.1001/archpsyc.65.6.6831851982610.1001/archpsyc.65.6.683PMC2430596 | β | β | β |
| YuanSMillerDWBarnettGHHahnJFWilliamsBR Identification and characterization of human beta 2-chimaerin: association with malignant transformation in astrocytoma. Cancer Res. 1995; 55: 3456Y34617614486 | β | β | β |
| ZhaoMHaoW. [Diagnosis and clinical management of amphetamine- induced psychosis]. Shanghai Arch Psychiatry. 2011; 23: 324-328. Chinese. doi: http://dx.chinadoi.cn/10.3969/j.issn.1002-0829.2011.06.001 | β | β | β |
In this knowledge base
| Title | Year | PMID |
|---|---|---|
| Genome-wide association study of stimulant dependence. | 2021 | 34226506 |
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Decoding Encoded Cravings: Epigenetic Drivers of Addiction. | Hediyal TA et al. | β | 2025 | β |
| Determining the diagnostic cut-off on the Chinese version of severity of dependence scale for DSM-5 stimulant use disorder. | Chung AKK et al. | β | 2025 | β |
| Research progress of DNA methylation on the regulation of substance use disorders and the mechanisms. | Liu Y et al. | β | 2025 | β |
| An update: epigenetic mechanisms underlying methamphetamine addiction. | Liu M et al. | β | 2024 | β |
| Epigenome-wide association study on methamphetamine dependence. | Shirai T et al. | β | 2024 | β |
| Functional modular networks identify the pivotal genes associated with morphine addiction and potential drug therapies. | Jiang Y et al. | β | 2023 | β |
| Epigenetic Regulatory Dynamics in Models of Methamphetamine-Use Disorder. | Jayanthi S et al. | β | 2021 | β |
| Genome-wide association study of stimulant dependence. | Cox J et al. | β | 2021 | β |
| Genome-Wide DNA Methylation Analysis in Male Methamphetamine Users With Different Addiction Qualities. | Liu L et al. | β | 2020 | β |
| Candidate Gene and Genome-Wide Association Studies for Circulating Leptin Levels Reveal Population and Sex-Specific Associations in High Cardiovascular Risk Mediterranean Subjects. | Ortega-AzorΓn C et al. | β | 2019 | β |
| Integrated genome-wide methylation and expression analyses reveal functional predictors of response to antidepressants. | Ju C et al. | β | 2019 | β |